Feasibility assessment of an all‐in‐one nerve repair and regeneration product

Projektinformationen

ULTRANERVE

ID Finanzhilfevereinbarung: 775155

DOI 10.3030/775155

Abgeschlossenes Projekt

EK-Unterschriftsdatum 23 Mai 2017

Startdatum 1 Juni 2017

Enddatum 30 September 2017

Finanziert unter

• INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies

Gesamtkosten € 71 429,00

EU-Beitrag € 50 000,00

Koordiniert durch

NERVE BIOMED SOCIEDAD LIMITADA
Spain

Ziel

Peripheral Nerve Injuries (PNIs) are lesions of the nerves of the head or the extremities. Grand View Research estimates over 2 million cases of PNIs per year in the EU and the USA. These injuries remain incurable, resulting in permanent loss of body function as in paraplegia, leading to disabilities and heavy social burden. The chance to cure PNIs based on smart nano-engineered biomaterials will have a major positive impact in heavy and long term burdens on patients and healthcare systems.

In this context, Nerve Biomed’s team, a spin-off company of the Polytechnic University of Valencia (Spain) has been leading an R&D initiative in advanced PNI reparation over the past 11 years, in order to develop and further commercialise ULTRANERVE: an easy-to-use medical solution for PNI regeneration, which is going to simplify medical procedures and reduce the average full recovery time, while decreasing significantly the average cost of actual repair procedures.

Within the roadmap established by the company to commercialize the product internationally by 2020, Nerve Biomed wants to perform a thorough feasibility study, through this SME Instrument Phase 1, which will assess in detail the practical and economic viability of introducing this solution in the PNI repair and regeneration market ih the EU and the USA.

Wissenschaftliches Gebiet

• medical and health sciences › basic medicine › pharmacology and pharmacy › pharmaceutical drugs
• medical and health sciences › clinical medicine › physiotherapy
• medical and health sciences › medical biotechnology › nanomedicine
• medical and health sciences › clinical medicine › oncology
• medical and health sciences › basic medicine › neurology

Programm/Programme

• H2020-EU.2.1.2. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies Main Programme
• H2020-EU.2.1.5. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced manufacturing and processing
• H2020-EU.2.1.3. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials
• H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument

Thema/Themen

• SMEInst-02-2016-2017 - Accelerating the uptake of nanotechnologies advanced materials or advanced manufacturing and processing technologies by SMEs

Aufforderung zur Vorschlagseinreichung

H2020-SMEInst-2016-2017

Andere Projekte für diesen Aufruf anzeigen

Unterauftrag

H2020-SMEINST-1-2016-2017

Finanzierungsplan

SME-1 - SME instrument phase 1

Koordinator

NERVE BIOMED SOCIEDAD LIMITADA

• Netto-EU-Beitrag: € 50 000,00
• Adresse: CALLE CANONIGO MOLINA ALONSO, NUM. 6 ; 04004 ALMERIA ; Spanien
• KMU Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen). Ja:
  Region
  Sur › Andalucía › Almería
• Region: Sur › Andalucía › Almería
• Aktivitätstyp: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Gesamtkosten: € 71 429,00